Kezar Life Sciences, Inc. - KZR STOCK NEWS

Kezar Life Sciences (NASDAQ: KZR) announced the grant of nonqualified stock options totaling 65,500 shares to four employees, exercising at $7.07 per share, equal to the stock's closing price on December 5, 2022. These options are part of an inducement award in accordance with Nasdaq Listing Rule 5635(c)(4) and will vest over four years. Kezar is focused on developing treatments for immune-mediated and oncologic disorders, with its lead candidate, Zetomipzomib, completing a Phase 2 trial for lupus nephritis and ongoing trials for KZR-261 targeting solid tumors.

Kezar Life Sciences, Inc. (KZR) reported positive results from the MISSION Phase 2 clinical trial of zetomipzomib for lupus nephritis (LN). Key findings include a significant increase in overall renal responses (ORR) from 64.7% to 88.2% by study’s end, with a median urine protein-to-creatinine ratio (UPCR) of 0.32. The treatment demonstrated a favorable safety profile, with no new safety signals and a reduction in corticosteroid use among participants. Results were presented at the ACR Convergence 2022, highlighting the potential of zetomipzomib for treating autoimmune diseases without immunosuppression.

Kezar Life Sciences, a clinical-stage biotechnology firm, announced the granting of a nonqualified stock option to one employee for 30,000 shares at an exercise price of $7.06 each. This decision aligns with Nasdaq's listing rules as an inducement for employment. The option will vest over four years, starting with 25% vested on the first anniversary of the employee's start date. Kezar is focused on developing innovative treatments for immune-mediated and oncologic disorders, including its lead candidate, Zetomipzomib, currently in clinical trials.

Kezar Life Sciences reported positive results from the MISSION Phase 2 trial for zetomipzomib in lupus nephritis, achieving an overall renal response in 64.7% of patients. The FDA granted IND clearance for this drug for treating autoimmune hepatitis. As of September 30, 2022, the company had $290.4 million in cash and equivalents, up from $208.4 million at the end of 2021. However, net loss for Q3 2022 was $17.8 million, compared to $14.5 million in Q3 2021, with increased R&D expenses.

Kezar Life Sciences, a clinical-stage biotechnology firm, has announced participation in two investor conferences this November. The Jefferies London Healthcare Conference will feature Dr. Noreen Roth Henig on November 16, 2022, at 8:35 AM GMT. The Evercore ISI HealthCONx Conference will include CEO John Fowler on November 30, 2022, at 12:10 PM ET. Both presentations will be available via webcast on their website for 90 days post-event. The company focuses on treatments for immune-mediated and oncologic disorders, notably their lead asset, Zetomipzomib.

Kezar Life Sciences announced positive results from the MISSION Phase 2 trial of zetomipzomib, a selective immunoproteasome inhibitor for lupus nephritis (LN). In 17 patients, the overall renal response rate (ORR) reached 64.7% at the end of treatment, improving to 88.2% during follow-up. Additionally, 35.3% achieved complete renal responses (CRR) at the end of treatment, increasing to 41.2% by study's end. The treatment demonstrated a favorable safety profile with no new safety signals. Kezar is planning further studies to explore zetomipzomib's full therapeutic potential.

Kezar Life Sciences (KZR) announced its participation at the ASN Kidney Week 2022 Annual Meeting in Orlando, FL, from November 3-6, where four posters will be presented. Key highlights include the full data from the Phase 2 MISSION trial on Zetomipzomib (KZR-616), a selective immunoproteasome inhibitor for lupus nephritis, demonstrating positive results from all 17 evaluable patients. More detailed findings will be shared beyond the abstract during the event, enhancing knowledge about KZR-616's potential in treating autoimmune diseases.

Kezar Life Sciences, Inc. (NASDAQ: KZR) announced the grant of nonqualified stock options for 85,000 shares to three employees, with an exercise price of $8.80 per share, matching the closing price on October 3, 2022. These options are part of an inducement award related to employment and will vest over four years. Kezar focuses on breakthrough treatments for immune-mediated and oncologic disorders, with products like Zetomipzomib and KZR-261 in clinical trials.

Kezar Life Sciences has received FDA clearance for its Investigational New Drug (IND) application of zetomipzomib (KZR-616) aimed at treating autoimmune hepatitis (AIH), a chronic condition affecting approximately 140,000 individuals in the U.S. This approval initiates the PORTOLA trial, a Phase 2a study focusing on the drug's safety and efficacy for patients not responding to standard treatments. The study aims to enroll 24 patients and evaluate treatment outcomes by measuring liver enzyme levels.